Review of Pembrolizumab and other Anti PD-1/PD-L1 Antibodies

Caleb P Gottlich Ms
Additional contact information
Caleb P Gottlich Ms: Orthopedic Surgery Department, Johns Hopkins School of Medicine, USA

Global Journal of Pharmacy & Pharmaceutical Sciences, 2018, vol. 6, issue 5, 102-104

Abstract: Immunotherapies are rapidly becoming favored amongst physicians for the treatment of various oncologic process due to their more favorable adverse reaction profile in addition to their increased ability to target specific cancer tissue as opposed to the usual widespread devastation of healthy tissue that can accompany chemotherapy and radiation therapy. One class of immunotherapies that has shown exquisite promise in terms of efficacy and limited immune related adverse events is the anti-PD-1/PD-L1 antibodies, which falls under the immunotherapy classification of check point inhibitor. In this paper, we will give a brief review of the background, mechanism, and side effects common to PD-L1/PD-1 inhibitors as a cancer therapy.

Keywords: juniper publishers:Journal of Pharmacy; Global Journal of Pharmacy; Pharmaceutical Sciences; Pharmacy & Pharmaceutical Sciences; pharmaceutical sciences journals; omics online; open access; drug discovery; Clinical Trials; juniper publishers open access journals; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555696.pdf (application/pdf)
https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555696.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jgjpps:v:6:y:2018:i:5:p:102-104

DOI: 10.19080/GJPPS.2018.06.555696

Access Statistics for this article

Global Journal of Pharmacy & Pharmaceutical Sciences is currently edited by Sophia Mathis

More articles in Global Journal of Pharmacy & Pharmaceutical Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().